文献速递白血病

天冬酰胺酶停用对接受日本儿童白血病研究协会ALL-02方案治疗的急性淋巴细胞白血病患儿结局的影响

Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol.
PubMed 文献 · Br J Haematol · 2023-03-09

在日本儿童白血病研究协会ALL-02前瞻性方案中,1192例患儿中88例(7.4%)停用L-天冬酰胺酶;因过敏停药较ALL-97方案明显减少(2.3% vs 15.4%)。T-ALL及高危B细胞ALL患儿停用L-天冬酰胺酶后无事件生存(EFS)受损,多因素分析显示停用是EFS的独立不良预后因素;额外化疗未能完全补偿停用。

要点

  • ALL-02方案中1192例患儿有88例(7.4%)停用L-天冬酰胺酶。
  • 因过敏停药比例ALL-02为2.3%,低于ALL-97方案的15.4%。
  • T-ALL和高危B细胞ALL患儿停用L-天冬酰胺酶后EFS受损。

核心结论

  • T-ALL和高危B细胞ALL患儿停用L-天冬酰胺酶后EFS受损,尤其在维持治疗前停用时。
  • 多因素分析确定停用L-天冬酰胺酶是EFS的独立不良预后因素。
  • 额外化疗未能完全补偿L-天冬酰胺酶停用,说明用其他类药物替代天冬酰胺酶存在困难。
  • 伴随的强化糖皮质激素治疗可能有助于减少对天冬酰胺酶的过敏。

研究设计与样本

  • 前瞻性日本儿童白血病研究协会ALL-02方案研究,纳入1192例患者。
  • ALL-02方案相对既往ALL-97方案有两项主要改变:停用天冬酰胺酶时增加化疗以补偿治疗强度降低,以及更强化地同时给予糖皮质激素。
  • 本研究并非设计用于评估上述方案修改的效果。

主要发现

  • ALL-02研究中1192例患者中88例(7.4%)停用L-天冬酰胺酶。
  • 因过敏停用L-天冬酰胺酶的比例ALL-02方案为2.3%,ALL-97方案为15.4%。
  • T-ALL患者停用L-天冬酰胺酶后EFS受损,高危B细胞ALL患者同样如此,尤其在维持治疗前停用时。
  • 多因素分析确定停用L-天冬酰胺酶是EFS的独立不良预后因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究并非设计用于评估额外化疗和强化糖皮质激素等方案修改的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Asparaginase is an essential drug for acute lymphoblastic leukaemia (ALL) treatment, but has several side effects, and its discontinuation often compromises patient outcomes. In the prospective Japan Association of Childhood Leukaemia Study ALL-02 protocol, two major changes were made: (1) additional chemotherapies to compensate for the reduction of treatment intensity when asparaginase was discontinued and (2) more intensive concomitant corticosteroid administration, relative to our previous ALL-97 protocol. In ALL-02 study, 1192 patients were included and L-asparaginase was discontinued for 88 (7.4%). Discontinuation due to allergy was markedly decreased relative to the ALL-97 protocol (2.3% vs 15.4%). Event-free survival (EFS) among patients with T-ALL was compromised when L-asparaginase was discontinued, as well as among patients with high-risk B-cell ALL, especially when discontinued before maintenance therapy. Moreover, multivariate analysis identified discontinuation of L-asparaginase as an independent poor prognostic factor for EFS. In the current study, additional chemotherapies failed to fully compensate for L-asparaginase discontinuation, illustrating the difficulty of replacing asparaginase with other classes of drugs, although this study was not designed to evaluate the effect of these modifications. Concomitant intensive corticosteroid treatment may help to reduce allergy to asparaginase. These results will assist in further optimization of asparaginase use.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ishida H, Imamura T, Tatebe Y, et al. Impact of asparaginase discontinuation on outcomes of children with acute lymphoblastic leukaemia receiving the Japan Association of Childhood Leukaemia Study ALL-02 protocol. Br J Haematol. 2023. PMID: 36891758. doi:10.1111/bjh.18745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。